Add to cart. AcipHex rabeprazole Tablet Slow-release AcipHex Sprinkle rabeprazole Capsule Slow-release; Note: contents are intended to be sprinkled on food or liquid but should not be chewed or crushed.
Acticlate doxycycline hyclate Capsule; Tablet Film-coated; tablet is scored and may be split; Note: mg tablets can be broken into two-thirds or one-third to provide a mg and 50 mg strength, respectively Actiq fenta NYL Lozenge Slow-release; Note: this lollipop delivery system requires the patient to slowly allow dissolution. Actonel risedronate Tablet Irritant; Note: chewed, crushed, or sucked tablets may cause oropharyngeal ulceration.
Copiktra develisib Capsule Antineoplastic Coreg CR carvedilol Capsule Slow-release a Note: may add contents of capsule to chilled, not warm, applesauce and consume immediately Cotempla XR-ODT methylphenidate Tablet Slow-release; oral disintegrating tablet designed to disintegrate on the tongue. Creon 5, 10, 20 pancrelipase Capsule Slow-release a Cresemba isavuconazium Capsule - Crixivan indinavir Capsule Taste; Note: capsule may be opened and mixed with fruit puree e.
List of Confused Drug Names. Medications requiring special safeguards to reduce the risk of errors and minimize harm. View all Recommendations. Irritant; Note: chewed, crushed, or sucked tablets may cause oropharyngeal ulceration. Slow-release; Note: chewed, cut, or crushed tablets may cause oropharyngeal irritation.
Sublingual form g ; Note: chewing or swallowing may result in lower bioavailability. Note: chewing or swallowing may result in lower peak concentrations and bioavailability.
Note: tablet should be swallowed whole and not crushed; tablet may be dispersed in water. Note: breaking, chewing, or emptying contents of the capsule can result in increased exposure. Teratogenic effects were observed in animal reproduction studies after administration of rifaximin to pregnant rats and rabbits during organogenesis at doses approximately 0. In rabbits, ocular, oral and maxillofacial, cardiac, and lumbar spine malformations were observed. Ocular malformations were observed in both rats and rabbits at doses that caused reduced maternal body weight gain.
Advise pregnant women of the potential risk to a fetus. There is no information regarding the presence of rifaximin in human milk, the effects of rifaximin on the breast-fed infant, or the effects of rifaximin on milk production.
Consider the development and health benefits of breast-feeding along with the mother's clinical need for rifaximin and any potential adverse effects on the breast-fed infant from rifaximin or from the underlying maternal condition. Acetaminophen; Caffeine; Dihydrocodeine: Moderate Concomitant use of dihydrocodeine with rifaximin can decrease dihydrocodeine levels, resulting in less metabolism by CYP2D6 and decreased dihydromorphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
If coadministration is necessary, monitor for reduced efficacy of dihydrocodeine and signs of opioid withdrawal; consider increasing the dose of dihydrocodeine as needed. If rifaximin is discontinued, consider a dose reduction of dihydrocodeine and frequently monitor for signs or respiratory depression and sedation. Dihydrocodeine is partially metabolized by CYP3A4. Rifaximin is a moderate CYP3A4 inducer in vitro; however, in patients with normal liver function, rifaximin at the recommended dosing regimen is not expected to induce CYP3A4.
It is unknown whether rifaximin can have a significant effect on the pharmacokinetics of concomitant CYP3A4 substrates in patients with reduced liver function who have elevated rifaximin concentrations. Acetaminophen; Codeine: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
It is recommended to avoid this combination when codeine is being used for cough. If coadministration is necessary, monitor for reduced efficacy of codeine and signs of opioid withdrawal; consider increasing the dose of codeine as needed. If rifaximin is discontinued, consider a dose reduction of codeine and frequently monitor for signs or respiratory depression and sedation. Acetaminophen; Hydrocodone: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
It is recommended to avoid this combination when hydrocodone is being used for cough. If coadministration is necessary, monitor for reduced efficacy of hydrocodone and signs of opioid withdrawal; consider increasing the dose of hydrocodone as needed.
If rifaximin is discontinued, consider a dose reduction of hydrocodone and frequently monitor for signs or respiratory depression and sedation.
Acetaminophen; Oxycodone: Moderate Monitor for reduced efficacy of oxycodone and signs of opioid withdrawal if coadministration with rifaximin is necessary; consider increasing the dose of oxycodone as needed. If rifaximin is discontinued, consider a dose reduction of oxycodone and frequently monitor for signs of respiratory depression and sedation. Concomitant use with CYP3A4 inducers can decrease oxycodone concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Amiodarone: Moderate Concurrent use of rifaximin, a P-glycoprotein P-gp substrate, and amiodarone, a P-gp inhibitor, may increase the systemic exposure to rifaximin; caution is advised if these drugs must be administered together. During an in vitro study, coadministration with a potent P-gp inhibitor resulted in an fold and fold increase in the mean Cmax and AUC of rifaximin, respectively.
In patients with hepatic impairment, the effects of reduced metabolism and P-gp inhibition may further increase exposure to rifaximin. Amoxicillin; Clarithromycin; Omeprazole: Moderate Although the clinical significance of this interaction is unknown, concurrent use of rifaximin, a P-glycoprotein P-gp substrate, and clarithromycin, a P-gp inhibitor, may substantially increase the systemic exposure to rifaximin; caution is advised if these drugs must be administered together. During one in vitro study, coadministration with cyclosporine, a potent P-gp inhibitor, resulted in an fold and fold increase in the mean Cmax and AUC of rifaximin, respectively.
Aspirin, ASA; Butalbital; Caffeine; Codeine: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Aspirin, ASA; Caffeine; Dihydrocodeine: Moderate Concomitant use of dihydrocodeine with rifaximin can decrease dihydrocodeine levels, resulting in less metabolism by CYP2D6 and decreased dihydromorphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Aspirin, ASA; Carisoprodol; Codeine: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Aspirin, ASA; Oxycodone: Moderate Monitor for reduced efficacy of oxycodone and signs of opioid withdrawal if coadministration with rifaximin is necessary; consider increasing the dose of oxycodone as needed.
Atazanavir: Moderate Although the clinical significance of this interaction is unknown, concurrent use of rifaximin and atazanavir may increase the systemic exposure to rifaximin; caution is advised if these drugs must be administered together.
Atazanavir; Cobicistat: Moderate Although the clinical significance of this interaction is unknown, concurrent use of rifaximin and atazanavir may increase the systemic exposure to rifaximin; caution is advised if these drugs must be administered together. During one in vitro study, coadministration with cyclosporine, a potent P-gp and OATP inhibitor, resulted in an fold and fold increase in the mean Cmax and AUC of rifaximin, respectively. Avapritinib: Minor Avoid coadministration of avapritinib with rifaximin in patients with hepatic impairment due to the risk of decreased avapritinib efficacy.
Avapritinib is a CYP3A4 substrate. In vitro, rifaximin is a CYP3A4 inducer. In patients with normal liver function, rifaximin at the recommended dosing regimen is not expected to induce CYP3A4. However, it is unknown whether rifaximin can have a significant effect on the pharmacokinetics of CYP3A4 substrates in patients with reduced liver function who have elevated rifaximin concentrations.
Axitinib: Moderate In patients with hepatic impairment, avoid coadministration of axitinib with rifaximin if possible due to the risk of decreased efficacy of axitinib. Selection of a concomitant medication with no or minimal CYP3A4 induction potential is recommended. In patients with normal hepatic function, rifaximin is not expected to induce CYP3A4 at the recommended dosing regimen. It is unknown whether rifaximin can have a significant effect on the pharmacokinetics of CYP3A4 substrates in patients with reduced liver function who have elevated rifaximin concentrations.
Bepridil: Moderate Although the clinical significance of this interaction is unknown, concurrent use of rifaximin, a P-glycoprotein P-gp substrate, and bepridil, a P-gp inhibitor, may increase the systemic exposure to rifaximin; caution is advised if these drugs must be administered together.
Berotralstat: Moderate Monitor for an increase in rifaximin-related adverse reactions if coadministration with berotralstat is necessary. Rifaximin is a P-glycoprotein P-gp substrate and berotralstat is a P-gp inhibitor. In patients with hepatic impairment, a potential additive effect of reduced metabolism may further increase systemic rifaximin exposure.
Concomitant use with another P-gp inhibitor increased the Cmax and AUC of rifaximin by fold and fold.
Boceprevir: Moderate Rifaximin is a substrate of P-gp and boceprevir is a P-gp inhibitor. Coadministation may result in increased plasma concentrations of rifaximin; use caution. In patients with hepatic impairment, reduced drug metabolism may increase the effects of P-gp inhibition.
Brigatinib: Moderate In patients with hepatic impairment, avoid coadministration of brigatinib with rifaximin due to decreased plasma exposure to brigatinib which may result in decreased efficacy; brigatinib may be administered with rifaximin in patients with normal hepatic function.
If concomitant use is unavoidable in patients with hepatic impairment, after 7 days of concomitant treatment with rifaximin, increase the dose of brigatinib as tolerated in 30 mg increments to a maximum of twice the original brigatinib dose.
After discontinuation of rifaximin, resume the brigatinib dose that was tolerated prior to initiation of rifaximin. Brigatinib is a CYP3A4 substrate. Brompheniramine; Guaifenesin; Hydrocodone: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Brompheniramine; Hydrocodone; Pseudoephedrine: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Butalbital; Acetaminophen; Caffeine; Codeine: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Cabozantinib: Moderate Rifaximin is a substrate of P-gp and cabozantinib is a P-gp inhibitor. Cannabidiol: Moderate Monitor for an increase in rifaximin-related adverse reactions if coadministration with cannabidiol is necessary.
Rifaximin is a P-gp substrate and cannabidiol is a P-gp inhibitor. Carbinoxamine; Hydrocodone; Phenylephrine: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Carbinoxamine; Hydrocodone; Pseudoephedrine: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Chlorpheniramine; Codeine: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Chlorpheniramine; Dihydrocodeine; Phenylephrine: Moderate Concomitant use of dihydrocodeine with rifaximin can decrease dihydrocodeine levels, resulting in less metabolism by CYP2D6 and decreased dihydromorphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Chlorpheniramine; Dihydrocodeine; Pseudoephedrine: Moderate Concomitant use of dihydrocodeine with rifaximin can decrease dihydrocodeine levels, resulting in less metabolism by CYP2D6 and decreased dihydromorphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Chlorpheniramine; Guaifenesin; Hydrocodone; Pseudoephedrine: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Chlorpheniramine; Hydrocodone: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Chlorpheniramine; Hydrocodone; Phenylephrine: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Chlorpheniramine; Hydrocodone; Pseudoephedrine: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Clarithromycin: Moderate Although the clinical significance of this interaction is unknown, concurrent use of rifaximin, a P-glycoprotein P-gp substrate, and clarithromycin, a P-gp inhibitor, may substantially increase the systemic exposure to rifaximin; caution is advised if these drugs must be administered together. Cobimetinib: Major The manufacturer of cobimetinib recommends avoiding concurrent with rifaximin due to decreased cobimetinib efficacy.
Codeine: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Codeine; Guaifenesin: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. Codeine; Guaifenesin; Pseudoephedrine: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Codeine; Phenylephrine; Promethazine: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Codeine; Promethazine: Moderate Concomitant use of codeine with rifaximin can decrease codeine levels, resulting in less metabolism by CYP2D6 and decreased morphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Conivaptan: Moderate Use caution when administering conivaptan and rifaximin concurrently. Conivaptan is an inhibitor of P-glycoprotein P-gp. Co-administration of conivaptan with P-gp substrates, such as rifaximin, can increase rifaximin exposure leading to increased or prolonged therapeutic effects and adverse events. The clinical significance of this increase in systemic exposure is unknown; thus, caution and close monitoring for adverse reactions is advised if these drugs must be administered together.
Dabigatran: Moderate Coadministration of dabigatran and rifaximin may result in increased dabigatran serum concentrations, increasing the risk of dabigatran adverse effects. Coadministration of dabigatran and rifaximin should be avoided in patients with severe renal impairment CrCl Daclatasvir: Major The dose of daclatasvir, a CYP3A4 substrate, may need to be increased to 90 mg PO once daily when administered in combination with rifaximin.
Rifaximin is categorized as a moderate CYP3A4 inducer; however in patients with normal hepatic function, rifaximin at the recommended dosing regimen is not expected to induce CYP3A4.
Taking these drugs together may decrease daclatasvir serum concentrations, potentially resulting in reduced antiviral efficacy and antimicrobial resistance.
Dasabuvir; Ombitasvir; Paritaprevir; Ritonavir: Moderate Although the clinical significance of this interaction is unknown, concurrent use of rifaximin, a P-glycoprotein P-gp substrate, and ritonavir, a P-gp inhibitor, may substantially increase the systemic exposure to rifaximin; caution is advised if these drugs must be administered together.
Moderate Concurrent administration of rifaximin with dasabuvir; ombitasvir; paritaprevir; ritonavir or ombitasvir; paritaprevir; ritonavir may result in elevated rifaximin and ombitasvir plasma concentrations and altered concentrations of dasabuvir, paritaprevir, and ritonavir. Rifaximin is a substrate and inhibitor of the drug transporter P-glycoprotein P-gp ; ritonavir and paritaprevir are P-gp inhibitors. Although ritonavir's effect on rifaximin clearance is not defined, coadministration with cyclosporine, a potent P-gp inhibitor, resulted in an fold and fold increase in rifaximin Cmax and AUC, respectively.
In patients with hepatic impairment, the reduced metabolism and P-gp inhibition may further increase rifaximin exposure. Dasabuvir, ombitasvir, paritaprevir, and ritonavir are also P-gp substrates.
In addition, ritonavir, paritaprevir, and dasabuvir minor are substrates of the hepatic isoenzyme CYP3A4. Rifaximin has been shown to be an inducer of CYP3A4, but enzyme induction is not expected when rifaximin is given at FDA-approved dosages in patients with normal liver function. It is not known whether rifaximin has a significant effect on the pharmacokinetics of CYP3A4 substrates in patients with hepatic impairment.
Caution and close monitoring are advised if these drugs are administered together. Moderate Monitor for an increase in adverse reactions related to either therapy if coadministration is necessary. Rifaximin is a substrate and inhibitor of the drug transporter P-glycoprotein P-gp ; ritonavir is a P-gp inhibitor. Deflazacort: Moderate Monitor for decreased efficacy of deflazacort if concomitant use of deflazacort and rifaximin is necessary.
Deflazacort is a CYP3A4 substrate. Rifaximin is a CYP3A4 inducer in vitro; however, in patients with normal liver function, rifaximin at the recommended dosing regimen is not expected to induce CYP3A4. Dextromethorphan; Quinidine: Moderate Although the clinical significance of this interaction is unknown, concurrent use of rifaximin, a P-glycoprotein P-gp substrate, and quinidine, a P-gp inhibitor, may substantially increase the systemic exposure to rifaximin; caution is advised if these drugs must be administered together.
Dihydrocodeine; Guaifenesin; Pseudoephedrine: Moderate Concomitant use of dihydrocodeine with rifaximin can decrease dihydrocodeine levels, resulting in less metabolism by CYP2D6 and decreased dihydromorphine concentrations; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Diphenhydramine; Hydrocodone; Phenylephrine: Moderate Concomitant use of hydrocodone with rifaximin can decrease hydrocodone levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence.
Doravirine: Moderate Concurrent administration of doravirine and rifaximin may result in decreased doravirine exposure, resulting in potential loss of virologic control. Doravirine is a CYP3A4 substrate. Doravirine; Lamivudine; Tenofovir disoproxil fumarate: Moderate Concurrent administration of doravirine and rifaximin may result in decreased doravirine exposure, resulting in potential loss of virologic control.
Doxorubicin: Major Avoid coadministration of rifaximin and doxorubicin if possible. If not possible, monitor doxorubicin closely for increased side effects including myelosuppression and cardiotoxicity. Oral rifaximin is largely unabsorbed and should not result in drug interactions. In vitro, rifaximin is a mild inhibitor of P-glycoprotein P-gp.
Doxorubicin is a major substrate of P-gp. Clinically significant interactions have been reported when doxorubicin was coadministered with inhibitors of P-gp, resulting in increased concentration and clinical effect of doxorubicin.
Dronabinol: Moderate Use caution if coadministration of dronabinol with rifaximin is necessary, and monitor for a decrease in the efficacy of dronabinol. Rifaximin is a moderate inducer of CYP3A4 in vitro; however, in patients with normal liver function, rifaximin at the recommended dosing regimen is not expected to induce CYP3A4.
Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here. As well, some forms of this medication may not be used for all of the conditions discussed here. Your doctor may have suggested this medication for conditions other than those listed in these drug information articles. If you have not discussed this with your doctor or are not sure why you are taking this medication, speak to your doctor.
Do not stop taking this medication without consulting your doctor. Do not give this medication to anyone else, even if they have the same symptoms as you do. It can be harmful for people to take this medication if their doctor has not prescribed it. Each pink, oval, biconvex tablet with "rfx" debossed on one side contains mg of rifaximin. Nonmedicinal ingredients : colloidal silicon dioxide, glyceryl distearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, red iron oxide, sodium starch glycolate, talc, and titanium dioxide.
For the prevention of hepatic encephalopathy , the recommended adult dose of rifaximin is mg taken 2 times a day. For the treatment of irritable bowel syndrome with diarrhea , the recommended adult dosage is one tablet taken 3 times a day. Rifaximin should be taken on an empty stomach.
Tablets should be swallowed whole with water. Do not crush or chew rifaximin tablets. Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
It is important that this medication be taken exactly as prescribed by your doctor. If you miss a dose, take it as soon as possible and continue with your regular schedule. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.
Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
Store this medication at room temperature, protect it from light and moisture, and keep it out of the reach of children. Do not dispose of medications in wastewater e. Ask your pharmacist how to dispose of medications that are no longer needed or have expired. Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses.
0コメント